miR-146a is also upregulated in AD and participates in the pathogenesis of this condition via targeting Lrp2 and inhibiting the Akt signaling pathway, modulating ROCK1 expression and decreasing Tau phosphorylation, and influencing inflammatory responses via modulation of IRAK-1 (Cui et al., 2010; Wang et al., 2016). The gene discussed is MAPT; the disease is Alzheimer disease.